EMA Panel Recommends Expanded Indication for Oncopeptides' Pepaxti

The EMA's CHMP has recommended approval of an expanded therapeutic indication for Oncopeptides' cancer drug Pepaxti, according to a company press release. The recommendation is a positive regulatory step but final approval by the European Commission is still pending. This is a company-specific development with limited immediate market-wide impact.